Postmenopausal women with osteoporosis: experience when treated with teriparatide in clinical practice

被引:4
|
作者
Ish-Shalom, Sophia [1 ]
Dumitrache, Constantin [2 ]
El-Husseini, Timour Fikry [3 ]
Hussein, Azza [4 ]
Barker, Clare [5 ]
Pavo, Imre [6 ]
机构
[1] Technion Fac Med, Bone & Mineral Metab Unit, Haifa, Israel
[2] CI Parhon Inst Endocrinol, Bucharest, Romania
[3] Ain Shams Univ, Fac Med, Dept Orthoped Surg, Cairo, Egypt
[4] Ain Shams Univ, Fac Med, Dept Rheumatol, Cairo, Egypt
[5] Lilly Res Labs UK, Surrey, England
[6] Lilly Reg Operat Vienna, Dept Med, Vienna, Austria
关键词
QUALITY-OF-LIFE; RADIOGRAPHIC VERTEBRAL FRACTURE; BONE-MINERAL DENSITY; BACK-PAIN; PARATHYROID-HORMONE; OLDER WOMEN; DISABILITY; DEFORMITIES; PREVALENT; RISK;
D O I
10.1185/03007995.2010.540007
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
To observe and compare back pain and health-related quality of life (HRQoL) in postmenopausal women with a prior unsatisfactory response to antiresorptive therapy, treated with teriparatide (TPTD) or alternative treatments in normal clinical practice. Prospective, observational, multicentre, 24-month study of postmenopausal women with osteoporosis. A back pain and HRQoL questionnaire (European Quality of Life Questionnaire, EQ-5D) including visual analogue scale (VAS) was completed at each visit. A total of 153 patients were enrolled, 105 patients started TPTD treatment during the study (TPTD cohort) and 48 patients did not take TPTD treatment at any time during the study (non-TPTD cohort). Four patients did not meet the inclusion criteria for the study. Of the patients in the non-TPTD cohort, 31 (68.9%) took antiresorptives during the study. The patients selected by the investigator for teriparatide treatment were distinctly different from those not selected. At baseline, the mean back pain VAS was greater in the TPTD than the non-TPTD cohort, 64 mm and 42 mm, respectively (p < 0.001). During the study, compared with baseline, the mean back pain VAS decreased in the TPTD cohort at all visits (p < 0.001). In the non-TPTD cohort, a transitory decrease in the mean after 12 months was observed (-10 mm, p = 0.023) only. After 24 months, the mean back pain VAS improved in the TPTD cohort (-36 mm, p < 0.001) while no change was observed in the non-TPTD cohort (-4 mm, p = 0.467). At baseline, the mean EQ-VAS was lower in the TPTD than in the non-TPTD cohort, 40.8 and 55.2, respectively (p < 0.001). After 24 months, EQ-VAS improved in both cohorts (TPTD 34, p < 0.001 and non-TPTD 9, p = 0.026). TPTD-treated patients had more back pain and lower HRQoL at baseline. In the TPTD cohort the mean value was consistently and significantly improved in back pain and quality of life. In the non-TPTD cohort, the mean improvement in back pain and QoL was inconsistent possibly due to the initially higher QoL and lower back pain leaving less room for improvement. These results should be interpreted in the context of limitations related to a non-randomised observational study.
引用
收藏
页码:343 / 353
页数:11
相关论文
共 50 条
  • [21] Teriparatide therapy and risk of hypercalciuria in postmenopausal women with osteoporosis.
    Miller, P.
    Bilezikian, J.
    Chen, P.
    Marin, F.
    Krege, J.
    Wong, M.
    Marcus, R.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2006, 21 : S299 - S299
  • [22] Effect of raloxifene after teriparatide treatment in postmenopausal women with osteoporosis
    Adami, S.
    Munoz-Torres, M.
    Econs, M. J.
    Sipos, A.
    Xie, L.
    Dalsky, G. P.
    McClung, M.
    Felsenberg, D.
    Brown, J. P.
    Brandi, M. L.
    San Martin, J.
    OSTEOPOROSIS INTERNATIONAL, 2006, 17 : S137 - S137
  • [23] The effects of teriparatide on the incidence of back pain in postmenopausal women with osteoporosis
    Genant, HK
    Halse, J
    Briney, WG
    Xie, L
    Glass, EV
    Krege, JH
    CURRENT MEDICAL RESEARCH AND OPINION, 2005, 21 (07) : 1027 - 1034
  • [24] Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment
    Miller, P. D.
    Schwartz, E. N.
    Chen, P.
    Misurski, D. A.
    Krege, J. H.
    OSTEOPOROSIS INTERNATIONAL, 2007, 18 (01) : 59 - 68
  • [25] Clinical experience with teriparatide for the treatment of osteoporosis.
    Bachrach, L.
    Camacho, P. M.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2006, 21 : S296 - S296
  • [26] PERSISTENCE TO DENOSUMAB IN WOMEN WITH POSTMENOPAUSAL OSTEOPOROSIS AT INCREASED FRACTURE RISK TREATED IN ROUTINE CLINICAL PRACTICE IN BULGARIA
    Monov, S.
    Nestorova, R.
    Velkova, M.
    Temelkova, N.
    Jeleva, S.
    Petkova, R.
    Petranova, T.
    OSTEOPOROSIS INTERNATIONAL, 2020, 31 (SUPPL 1) : S442 - S443
  • [27] Improvement of the persistence with teriparatide in postmenopausal osteoporosis: The French experience of an education program
    Briot, K.
    Ravaud, P.
    Liu-Leage, S.
    Roux, C.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2007, 22 : S213 - S213
  • [28] Improvement of the persistence with teriparatide in postmenopausal osteoporosis:: The french experience of an education program
    Briot, K.
    Ravaud, P.
    Liu-Leage, S.
    Roux, C.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2007, 22 : S508 - S508
  • [29] Factors associated with bone response to teriparatide in young postmenopausal women with osteoporosis
    Anna, Gosset
    Anne-Lise, Farcy
    Clemence, Dufond
    Jean-Michel, Pouilles
    Florence, Tremollieres
    JOURNAL OF BONE AND MINERAL METABOLISM, 2023, 41 (2) : 278 - 285
  • [30] Response to Comparison of Teriparatide and Strontium Ranelate in Postmenopausal Women With Osteoporosis Reply
    Recker, Robert R.
    Ish-Shalom, Sophia
    Marin, Fernando
    Hawkins, Federico
    Stepan, Jan
    JOURNAL OF BONE AND MINERAL RESEARCH, 2009, 24 (12) : 2067 - 2068